Replies to post #727 on Trillium Therapeutics Inc (TRIL)

[Inoviorulez]

Here is the scenario I see playing out for TRIL. On the presentation they stated they expect to partner STING by 1st half of 2020. I think such a partnership with upfront cash/milestones takes it to $8 pere share or $10 per share in the short-term.

I believe that $40 per share will be achieved once the mid-2020 update happens. That's because that's when it will select its dose to move forward for phase 2 in combination for TTI-622 like FTSV.

For TTI-621 it continues to achieve complete response rates and that will move on also.

But I think on a positive mid-2020 update you can easily see $40 per share. If everything aligns right that day.